The HORMAD1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population designed for the study of HORMAD1 function in a cancer-relevant background. This loss-of-function model is generated by introducing targeted disruptions into the HORMAD1 locus of HeLa cells, yielding a heterogeneous pool of knockout cells that enables robust investigation of HORMAD1-dependent processes without clonal selection artifacts. The polyclonal format preserves population-level diversity, making it particularly suited for experiments where clone-specific effects are undesirable, such as pooled functional screens, signaling studies, or assays requiring a representative cellular response.
HeLa cells, the host line for this knockout model, are an HPV18-immortalized epithelial line derived from a cervical adenocarcinoma. They are among the most widely employed human cell models in biomedical research and have been instrumental in dissecting pathways relevant to cancer biology, DNA damage responses, and therapeutic resistance. Their well-characterized growth kinetics, genetic tractability, and extensive historical datasets provide a reliable platform for interrogating the role of aberrantly expressed germline genes in tumorigenesis. The introduction of a HORMAD1 disruption in this context allows researchers to examine its contributions to malignant phenotypes directly.
HORMAD1 encodes a meiotic protein that is normally restricted to germ cells, where it is essential for synaptonemal complex formation and homologous chromosome synapsis during prophase I. In this role, HORMAD1 interacts with multiple structural components, including SYCP1, SYCP2, SYCP3, SMC1B, and SYCE1, and contributes to the regulation of DNA double-strand break repair through BRCA1 and RAD51. Aberrant expression of HORMAD1 in somatic tissues, often driven by upstream regulators such as DMRT1, SP1, and CpG island hypomethylation, is associated with genomic instability. The protein??s downstream effects extend to the transcriptional modulation of key meiotic and repair factors, linking HORMAD1 to broader chromosomal integrity networks involving REC8 and STAG3.
In the HeLa context, reactivation of HORMAD1 as a cancer/testis antigen creates a unique opportunity to study its pathologic functions. While HeLa cells are of somatic origin, they frequently exhibit promiscuous expression of germline?specific genes, making this knockout model a relevant system to dissect how HORMAD1 impinges on DNA repair fidelity and cell cycle control in a transformed setting. Loss-of-function studies can reveal whether HORMAD1 contributes to oncogenic genomic instability or susceptibility to DNA-damaging agents, providing insights that are directly translatable to tumors with HORMAD1 upregulation.
These polyclonal knockout cells are suitable for a variety of research applications, including cancer biology investigations, DNA repair pathway analysis, and cancer/testis antigen immunotherapy target validation. Confirmatory assays such as Western blotting and RT-qPCR can verify HORMAD1 protein and transcript disruption, while immunofluorescence can assess synaptonemal complex?Crelated localization changes. Functional studies may employ ??-H2AX foci assays to measure DNA damage levels, flow cytometry for cell cycle perturbations, and MTT viability assays to probe chemosensitivity. For additional technical information or customer support, please contact Ascent Research.
